Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 12,000 shares at $2.39 ($29K) on 2014-10-06, disclosed to the SEC on 2014-10-08.
Scheduled sale ($29k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.38 | 700 | $2K | 5.8% |
| 2 | $2.39 | 3,062 | $7K | 25.4% |
| 3 | $2.39 | 800 | $2K | 6.6% |
| 4 | $2.40 | 4,200 | $10K | 35.1% |
| 5 | $2.40 | 2,138 | $5K | 17.8% |
| 6 | $2.41 | 1,000 |
| $2K |
| 8.4% |
| 7 | $2.41 | 100 | $241 | 0.8% |
| Total | $2.40 avg | 12,000 | $29K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |